Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad.

Koyalta D, Charpentier C, Beassamda J, Rey E, Si-Mohamed A, Djemadji-Oudjeil N, BĂ©lec L.

Clin Infect Dis. 2009 Jul 1;49(1):155-9. doi: 10.1086/599611.

PMID:
19480574
2.

Development of anti-retroviral resistance of HIV-1 infected individuals on therapy: is it inevitable?

Kolber MA, Campo RE, Dickinson GM.

IUBMB Life. 2004 Jun;56(6):301-7. Review.

3.

Initial antiretroviral therapy in chronically-infected HIV-positive adults.

Temesgen Z, Cainelli F, Warnke D, Koirala J; Collaborative Research Network (CORNET) Investigators.

Expert Opin Pharmacother. 2004 Mar;5(3):595-612. Review.

PMID:
15013928
4.

Clinical management of HIV-1 resistance.

Paredes R, Clotet B.

Antiviral Res. 2010 Jan;85(1):245-65. doi: 10.1016/j.antiviral.2009.09.015. Epub 2009 Oct 4. Review.

PMID:
19808056
5.

Limits to potent antiretroviral therapy.

Telenti A, Paolo Rizzardi G.

Rev Med Virol. 2000 Nov-Dec;10(6):385-93. Review.

PMID:
11114077
6.

The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa.

Hamers RL, Derdelinckx I, van Vugt M, Stevens W, Rinke de Wit TF, Schuurman R; PharmAccess African Studies to Evaluate Resistance Programme.

Antivir Ther. 2008;13(5):625-39. Review. Erratum in: Antivir Ther. 2008;13(8):1129.

PMID:
18771046
7.

Treatment strategies for highly treatment-experienced HIV-infected patients.

Luber AD.

Expert Rev Anti Infect Ther. 2005 Oct;3(5):815-23. Review.

PMID:
16207173
8.

Treating primary HIV infection--is your HAART in it?

Smith DE, Chan DJ.

Sex Health. 2004;1(3):131-5. Review. No abstract available.

PMID:
16335299
9.

Incorporating drug-resistance measurements into the clinical management of HIV-1 infection.

Zolopa AR.

J Infect Dis. 2006 Sep 15;194 Suppl 1:S59-64. Review.

PMID:
16921474
10.

Antiretroviral regimens for treatment-experienced patients with HIV-1 infection.

Lagnese M, Daar ES.

Expert Opin Pharmacother. 2008 Apr;9(5):687-700. doi: 10.1517/14656566.9.5.687. Review.

PMID:
18345948
11.

Role of the inhibitory quotient in HIV therapy.

Hoefnagel JG, Koopmans PP, Burger DM, Schuurman R, Galama JM.

Antivir Ther. 2005;10(8):879-92. Review.

PMID:
16430193
12.

HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations.

Wilson LE, Gallant JE.

Clin Infect Dis. 2009 Jan 15;48(2):214-21. doi: 10.1086/595701. Review.

PMID:
19072245
13.

Drug-resistant human immunodefiency virus.

Kozal MJ.

Clin Microbiol Infect. 2009 Jan;15 Suppl 1:69-73. doi: 10.1111/j.1469-0691.2008.02687.x. Review.

14.

[AIDS treatment in Africa: the risk of antiretroviral resistance].

Hamers RL, Schuurman R, van Vugt M, Derdelinckx I, Rinke de Wit TF.

Ned Tijdschr Geneeskd. 2007 Dec 1;151(48):2666-71. Review. Dutch.

PMID:
18179083
15.

Strategies of HIV management--when to switch.

Youle M.

AIDS. 2002;16 Suppl 4:S151-5. Review. No abstract available.

PMID:
12699012
16.

New developments in HIV drug resistance.

Cane PA.

J Antimicrob Chemother. 2009 Sep;64 Suppl 1:i37-40. doi: 10.1093/jac/dkp258. Review.

PMID:
19675018
18.

Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching.

Elliott JH, Lynen L, Calmy A, De Luca A, Shafer RW, Zolfo M, Clotet B, Huffam S, Boucher CA, Cooper DA, Schapiro JM.

AIDS. 2008 Oct 18;22(16):2053-67. doi: 10.1097/QAD.0b013e328309520d. Review. No abstract available.

PMID:
18753937
19.

Managing antiretroviral therapy: changing regimens, resistance testing, and the risks from structured treatment interruptions.

Eron JJ.

J Infect Dis. 2008 May 15;197 Suppl 3:S261-71. doi: 10.1086/533418. Review.

PMID:
18447612
20.

Effect of introduction of highly active antiretroviral treatment and the changes in patterns of drug-resistant HIV-1 in Japan.

Sugiura W.

J Infect Chemother. 2001 Sep;7(3):127-32. Review. No abstract available.

PMID:
11810573

Supplemental Content

Support Center